Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Vomiting 3Nausea 3Lymphoma 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Papillomavirus Infections 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Inflammatory Breast Neoplasms 1Gynecologic Cancer 1Colonic Neoplasms 1Carcinoma in Situ 1Burkitt Lymphoma 1Breast Neoplasms, Male 1

Interventions

Doxorubicin 6Ifosfamide 5Radiotherapy 4pazopanib 3cediranib 3atezolizumab 3Sunitinib 3selinexor 2perifosine 2pembrolizumab 2Trabectedin 2Specimen Handling 2Loperamide 2Gemcitabine 2Filgrastim 2Dacarbazine 2Cisplatin 2Biopsy 2Bevacizumab 2trifluridine tipiracil drug combination 1spartalizumab 1sargramostim 1romidepsin 1lentiviral minigene vaccine of COVID-19 coronavirus 1ixazomib 1indolepropanol phosphate 1futibatinib 1fludarabine 1cabozantinib 1brostallicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Alveolar Soft Part × Prochlorperazine × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡